- Home
- REPX vs NPCE Comparison
REPX vs NPCE Comparison
Compare REPX & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$14.05
Company Overview
Basic Information| Metric | REPX | NPCE |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.9M | 485.6M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | REPX | NPCE |
|---|---|---|
| Price | $33.20 | $14.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $36.00 | $18.33 |
| AVG Volume (30 Days) | ★ 354.4K | 198.5K |
| Earning Date | 06-02-2026 | 05-25-2026 |
| Dividend Yield | ★ 4.74% | N/A |
| EPS Growth | ★ 78.17 | 29.03 |
| EPS | ★ 7.59 | N/A |
| Revenue | $3,038,000.00 | ★ $99,986,000.00 |
| Revenue This Year | $20.94 | $0.93 |
| Revenue Next Year | $11.13 | $25.47 |
| P/E Ratio | $4.45 | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $21.98 | $7.56 |
| 52 Week High | $34.32 | $18.97 |
Technical Indicators
Market Signals| Indicator | REPX | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 69.13 | 42.38 |
| Support Level | $26.51 | $12.47 |
| Resistance Level | N/A | $16.96 |
| Average True Range (ATR) | 1.30 | 0.82 |
| MACD | 0.41 | 0.04 |
| Stochastic Oscillator | 85.12 | 46.20 |
Price Performance
Historical Comparison REPX
NPCE
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.